Key result
MSC therapy may improve post-MI recovery by suppressing myofibroblast GLIPR1 to drive TIMP3-mediated matrix remodeling.
Why the study?
Molecular pathways of cardiac remodeling post-MI remain poorly understood, and effective therapies are lacking, with aged models needed to better reflect clinical scenarios.
Does mesenchymal stem cell therapy modulate GLIPR1 expression in cardiac fibroblasts following myocardial infarction in mouse models?
Does mesenchymal stem cell therapy modulate GLIPR1 expression in cardiac fibroblasts following myocardial infarction in mouse models?
GLIPR1 is identified as a key mediator of cardiac fibrosis post-MI that is upregulated by aging and suppressed by mesenchymal stem cell therapy, highlighting a potential therapeutic target.
Supports GLIPR1 as antifibrotic target in post-MI mouse models; leaves open clinical translation.
Despite recent advances in pre-clinical research on cardiac remodeling following myocardial infarction (MI), the precise molecular pathways remain poorly understood and effective therapies for heart failure are still delayed in development. Aged animal models may more accurately reflect the clinical scenario, as aging alters the cellular identities and impedes cardiac repair. In this manuscript, we investigated the expression profile of mouse cardiac fibroblasts following myocardial infarction, using both young and aged animals to enhance the translational significance. The initial studies aimed to identify fibroblast changes common to both young and old animals. Additionally, a group of young animals that underwent mesenchymal stem cells (MSC) therapy after MI surgery was included to help identify the molecular changes amenable to therapeutic modulation. The analysis uncovered Glioma- Pathogenesis Related Protein 1 (GLIPR1) activation during the post-MI maturation phase in a subset of myofibroblasts, localized to the infarct zone in young subjects and widespread throughout the ventricle in aged animals. Further investigations indicated that the inflammatory environment post-MI induced the upregulation of GLIPR1, which in turn promoted increased TIMP3 expression. These findings provide valuable insights for future research aimed at exploring the therapeutic potential of targeting GLIPR1 to reduce cardiac fibrosis post-MI. • GLIPR1 is upregulated in cardiac fibroblasts within infarcted areas of murine hearts. • Aging promotes GLIPR1 widespread expression in the entire infarcted ventricle. • MSC therapy impacts the cardiac fibroblasts even at later stages of post-MI repair. • GLIPR1 is associated to matrix remodeling through a direct impact on TIMP3. • MSCs may exert therapeutic effects by suppressing GLIPR1 in myofibroblasts.
No takes yet. Share an insight, caveat, or question.
Marinescu et al. (2025) studied Myocardial infarction. Mesenchymal stem cell (MSC) therapy vs. No MSC therapy was evaluated on GLIPR1 expression and cardiac fibroblast changes. Mesenchymal stem cell therapy may exert therapeutic effects post-myocardial infarction by suppressing GLIPR1 in myofibroblasts, which is associated with matrix remodeling through TIMP3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: